Avishai Levy
Co-founder & CEO
Claimed by owner ApoRx Biopharmaceuticals
Former names:
Targeted Protein Degradation Drug Discovery
ApoRx Biopharmaceuticals
About
ApoRx is a drug-discovery company focusing on the discovery, design, characterization, and development of small proteolysis-targeting molecules against well-validated disease-causing proteins in cancer and other indications.
The core of its technology is the Aperion library, a proprietary focus library of RING E3 ligase binders that is designed to harness the intracellular ubiquitin-proteasome machinery to degrade and destroy unwanted proteins via targeted protein degradation.
ApoRx is a subsidiary of Agbiopro Protein Degradation Hub, a management and consulting firm.
The core of its technology is the Aperion library, a proprietary focus library of RING E3 ligase binders that is designed to harness the intracellular ubiquitin-proteasome machinery to degrade and destroy unwanted proteins via targeted protein degradation.
ApoRx is a subsidiary of Agbiopro Protein Degradation Hub, a management and consulting firm.
Primary Sector
Life Sciences & HealthTech
Products
-
Geographic markets
-
Funding
Total Funding
Undisclosed
Last Funding
Undisclosed
Funding Stage
Total Rounds
0
Investors
0
News
(0)The Team
(4)
AL
OE
Omri Erez
Founder
PN
Philippe Nakache
Co-founder
Orna Harel
Co-founder
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Media gallery
(0)Locations
Israel
Ness Ziona, Israel
Locations
Israel
Ness Ziona, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,